Key Summary
- MHRA has approved a 1 mg EURneffy adrenaline (epinephrine) nasal spray for emergency treatment of anaphylaxis in children aged 4+.
- Patients should carry two sprays.
- This expands options beyond the existing 2 mg product (for 10+ years or ≥30 kg); the MHRA will continue monitoring the spray’s safety and effectiveness.
The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised a lower-strength version of the adrenaline (epinephrine) nasal spray EURneffy for emergency treatment of anaphylaxis in children aged four and up.
This decision makes a needle-free option available to younger children in the UK for the first time.
The new 1 mg spray is intended for children aged 4 years and older who weigh between 15 kg and 30 kg, expanding options beyond the existing 2 mg product that is approved for adults and children aged 10 years and above who weigh at least 30 kg.
Adrenaline is the established first-line treatment for severe allergic reactions and should be administered immediately at the first signs of anaphylaxis, before professional medical help arrives.
The nasal spray is designed to deliver the dose into the nostril and can be used even if it is congested.
Patients should carry two sprays, as a second dose may be required while awaiting ambulance arrival, and emergency services (999) must be contacted right after administration.
Until now, younger children typically relied on injectable adrenaline devices; the 1 mg nasal option offers an alternative. The MHRA said it will continue to closely review the product’s safety and effectiveness.
